|Systematic (IUPAC) name|
|1-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5- (trifluoromethyl) pyrimidine-2,4-dione|
|Legal status||℞ Prescription only|
|Mol. mass||296.2 g/mol|
| (what is this?)
Trifluridine (also called trifluorothymidine or TFT) is an anti-herpesvirus antiviral drug, used primarily on the eye. It was sold under the trade name, Viroptic, by Glaxo Wellcome, now merged into GlaxoSmithKline. The brand is now owned by Monarch Pharmaceuticals, which is wholly owned by King Pharmaceuticals.
It is a component of the experimental anti-cancer drug TAS-102.
- Costin D, Dogaru M, Popa A, Cijevschi I (2004). "Trifluridine therapy in herpetic in keratitis". Rev Med Chir Soc Med Nat Iasi 108 (2): 409–12. PMID 15688823.
- Kuster P, Taravella M, Gelinas M, Stepp P (1998). "Delivery of trifluridine to human cornea and aqueous using collagen shields.". CLAO J 24 (2): 122–4. PMID 9571274.
- O'Brien W, Taylor J (1991). "Therapeutic response of herpes simplex virus-induced corneal edema to trifluridine in combination with immunosuppressive agents.". Invest Ophthalmol Vis Sci 32 (9): 2455–61. PMID 1907950.
- "Trifluridine Ophthalmic Solution, 1%" (PDF). Retrieved 2007-03-24.
|This antiinfective drug article is a stub. You can help Wikipedia by expanding it.|